220 related articles for article (PubMed ID: 30796651)
1. Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study.
Wuerstlein R; Kates R; Gluz O; Grischke EM; Schem C; Thill M; Hasmueller S; Köhler A; Otremba B; Griesinger F; Schindlbeck C; Trojan A; Otto F; Knauer M; Pusch R; Harbeck N;
Breast Cancer Res Treat; 2019 Jun; 175(2):389-399. PubMed ID: 30796651
[TBL] [Abstract][Full Text] [Related]
2. The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer.
Wuerstlein R; Sotlar K; Gluz O; Otremba B; von Schumann R; Witzel I; Schindlbeck C; Janni W; Schem C; Bauerfeind I; Hasmueller S; Tesch H; Paulenz A; Ghali N; Orujov E; Kates RE; Cowens W; Hornberger J; Pelz E; Harbeck N
Curr Med Res Opin; 2016 Jul; 32(7):1217-24. PubMed ID: 26971372
[TBL] [Abstract][Full Text] [Related]
3. Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping.
Whitworth P; Beitsch P; Mislowsky A; Pellicane JV; Nash C; Murray M; Lee LA; Dul CL; Rotkis M; Baron P; Stork-Sloots L; de Snoo FA; Beatty J
Ann Surg Oncol; 2017 Mar; 24(3):669-675. PubMed ID: 27770345
[TBL] [Abstract][Full Text] [Related]
4. Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy.
Glück S; de Snoo F; Peeters J; Stork-Sloots L; Somlo G
Breast Cancer Res Treat; 2013 Jun; 139(3):759-67. PubMed ID: 23756626
[TBL] [Abstract][Full Text] [Related]
5. Comparison of molecular subtyping with BluePrint, MammaPrint, and TargetPrint to local clinical subtyping in breast cancer patients.
Nguyen B; Cusumano PG; Deck K; Kerlin D; Garcia AA; Barone JL; Rivera E; Yao K; de Snoo FA; van den Akker J; Stork-Sloots L; Generali D
Ann Surg Oncol; 2012 Oct; 19(10):3257-63. PubMed ID: 22965266
[TBL] [Abstract][Full Text] [Related]
6. The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER+, HER2- early breast cancer.
Exner R; Bago-Horvath Z; Bartsch R; Mittlboeck M; Retèl VP; Fitzal F; Rudas M; Singer C; Pfeiler G; Gnant M; Jakesz R; Dubsky P
Br J Cancer; 2014 Aug; 111(5):837-42. PubMed ID: 25003667
[TBL] [Abstract][Full Text] [Related]
7. MammaPrint guides treatment decisions in breast Cancer: results of the IMPACt trial.
Soliman H; Shah V; Srkalovic G; Mahtani R; Levine E; Mavromatis B; Srinivasiah J; Kassar M; Gabordi R; Qamar R; Untch S; Kling HM; Treece T; Audeh W
BMC Cancer; 2020 Jan; 20(1):81. PubMed ID: 32005181
[TBL] [Abstract][Full Text] [Related]
8. Genomic profiling of breast cancer in African-American women using MammaPrint.
Nunes RA; Wray L; Mete M; Herbolsheimer P; Smith KL; Bijelic L; Boisvert ME; Swain SM
Breast Cancer Res Treat; 2016 Oct; 159(3):481-8. PubMed ID: 27568021
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial.
Viale G; de Snoo FA; Slaets L; Bogaerts J; van 't Veer L; Rutgers EJ; Piccart-Gebhart MJ; Stork-Sloots L; Glas A; Russo L; Dell'Orto P; Tryfonidis K; Litière S; Cardoso F;
Breast Cancer Res Treat; 2018 Jan; 167(1):123-131. PubMed ID: 28929359
[TBL] [Abstract][Full Text] [Related]
10. Chemosensitivity predicted by BluePrint 80-gene functional subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST).
Whitworth P; Stork-Sloots L; de Snoo FA; Richards P; Rotkis M; Beatty J; Mislowsky A; Pellicane JV; Nguyen B; Lee L; Nash C; Gittleman M; Akbari S; Beitsch PD
Ann Surg Oncol; 2014 Oct; 21(10):3261-7. PubMed ID: 25099655
[TBL] [Abstract][Full Text] [Related]
11. Molecular subtyping improves diagnostic stratification of patients with primary breast cancer into prognostically defined risk groups.
Yao K; Goldschmidt R; Turk M; Wesseling J; Stork-Sloots L; de Snoo F; Cristofanilli M
Breast Cancer Res Treat; 2015 Nov; 154(1):81-8. PubMed ID: 26424167
[TBL] [Abstract][Full Text] [Related]
12. Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype-Prosigna® Test in the management of early-stage breast cancers.
Hequet D; Callens C; Gentien D; Albaud B; Mouret-Reynier MA; Dubot C; Cottu P; Huchon C; Zilberman S; Berseneff H; Foa C; Salmon R; Roulot A; Lerebours F; Salomon A; Ghali N; Morel P; Li Q; Cayre A; Guinebretière JM; Hornberger J; Penault-Llorca F; Rouzier R
PLoS One; 2017; 12(10):e0185753. PubMed ID: 29045452
[TBL] [Abstract][Full Text] [Related]
13. The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use.
Eiermann W; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Schneeweiss A; Markmann S; Eggemann H; Hilfrich J; Jackisch C; Witzel I; Eidtmann H; Bachinger A; Hell S; Blohmer J
Ann Oncol; 2013 Mar; 24(3):618-24. PubMed ID: 23136233
[TBL] [Abstract][Full Text] [Related]
14. The Impact of the Oncotype DX Breast Cancer Assay on Treatment Decisions for Women With Estrogen Receptor-Positive, Node-Negative Breast Carcinoma in Hong Kong.
Leung RC; Yau TC; Chan MC; Chan SW; Chan TW; Tsang YY; Wong TT; Chao C; Yoshizawa C; Soong IS; Kwan WH; Kwok CC; Suen JS; Ngan RK; Cheung PS
Clin Breast Cancer; 2016 Oct; 16(5):372-378. PubMed ID: 27105769
[TBL] [Abstract][Full Text] [Related]
15. Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer.
Sanft T; Aktas B; Schroeder B; Bossuyt V; DiGiovanna M; Abu-Khalaf M; Chung G; Silber A; Hofstatter E; Mougalian S; Epstein L; Hatzis C; Schnabel C; Pusztai L
Breast Cancer Res Treat; 2015 Dec; 154(3):533-41. PubMed ID: 26578401
[TBL] [Abstract][Full Text] [Related]
16. Use of adjuvant chemotherapy in hormone receptor-positive breast cancer patients with or without the 21-gene expression assay.
Park SJ; Lee MH; Kong SY; Song MK; Joo J; Kwon Y; Lee EG; Han JH; Sim SH; Jung SY; Lee S; Lee KS; Park IH; Lee ES
Breast Cancer Res Treat; 2018 Jul; 170(1):69-76. PubMed ID: 29516374
[TBL] [Abstract][Full Text] [Related]
17. A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response.
Krijgsman O; Roepman P; Zwart W; Carroll JS; Tian S; de Snoo FA; Bender RA; Bernards R; Glas AM
Breast Cancer Res Treat; 2012 May; 133(1):37-47. PubMed ID: 21814749
[TBL] [Abstract][Full Text] [Related]
18. Potential impact of the 70-gene signature in the choice of adjuvant systemic treatment for ER positive, HER2 negative tumors: a single institution experience.
Torrisi R; Garcia-Etienne CA; Losurdo A; Morenghi E; Di Tommaso L; Gatzemeier W; Sagona A; Fernandes B; Rossetti C; Eboli M; Rubino A; Barbieri E; Andreoli C; Orefice S; Gandini C; Rota S; Zuradelli M; Masci G; Santoro A; Tinterri C
Breast; 2013 Aug; 22(4):419-24. PubMed ID: 23643803
[TBL] [Abstract][Full Text] [Related]
19. Treatment response and 5-year distant metastasis-free survival outcome in breast cancer patients after the use of MammaPrint and BluePrint to guide preoperative systemic treatment decisions.
Göker E; Hendriks MP; van Tilburg M; Barcaru A; Mittempergher L; van Egmond A; Kleijn M; Generali D;
Eur J Cancer; 2022 May; 167():92-102. PubMed ID: 35421703
[TBL] [Abstract][Full Text] [Related]
20. Genomic Impact of Neoadjuvant Therapy on Breast Cancer: Incomplete Response is Associated with Altered Diagnostic Gene Signatures.
Beitsch P; Whitworth P; Baron P; Pellicane J; Treece T; Yoder E; Gittleman M;
Ann Surg Oncol; 2016 Oct; 23(10):3317-23. PubMed ID: 27384749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]